Bosanjin Engages in Korea-Japan Advanced Medical Exchange... Holds Regenerative Medicine Symposium with Japan's AMED

The Korea Health Industry Development Institute (KHIDI) announced on the 30th that it recently held the 'KHIDI-AMED Korea-Japan Joint Symposium on Regenerative Medicine' in Tokyo, Japan, in collaboration with the Japan Agency for Medical Research and Development (AMED). AMED is an integrated management organization for research and development (R&D) in the medical field in Japan, established in 2015.

Participants of the 'KHIDI-AMED Korea-Japan Joint Symposium on Regenerative Medicine' held in Tokyo, Japan, are taking a commemorative photo.
[Photo by Korea Health Industry Development Institute]

This symposium was organized as a result of ongoing discussions on cooperation between the two organizations following the first meeting in April between KHIDI President Cha Sun-do and AMED Chairman Yoshinao Mishima. Attendees included President Cha Sun-do, Chairman Mishima, and Masashi Hara, Director of the Japanese Ministry of Education, Culture, Sports, Science and Technology.

The symposium, focused on regenerative medicine, invited researchers specializing in genome editing technology and cell therapy to present the latest R&D trends and achievements from both countries and to exchange opinions on future joint research collaborations.

From Korea, participants included Professor Song Ji-hwan of CHA University, who presented research on Huntington's disease stem cell therapy that reduces cell transplantation rejection, as well as Yoo Jong-sang, CEO of Apicell Therapeutics, Professor Bae Sang-soo of Seoul National University, and Professor Sung Young-hoon of Asan Medical Center. Japanese speakers included Professor Shuji Terai of Niigata University, who presented research related to non-alcoholic steatohepatitis (NASH) treatment, Professor Hideyuki Okano of Keio University School of Medicine, Professor Akitsu Hota of Kyoto University, and Professor Yutaka Hanazono of Jichi Medical University. The event was held both online and offline, with approximately 170 attendees.

AMED Chairman Yoshinao Mishima stated, "It is meaningful that KHIDI and AMED reviewed and discussed each other's areas of interest and selected regenerative medicine as the theme for this symposium." He added, "We hope to continue exploring mutual areas of interest between Korean and Japanese researchers and expand cooperation." KHIDI President Cha Sun-do also remarked, "Taking this symposium as an opportunity, KHIDI and AMED will continue to strive to create a platform for diverse information sharing and ongoing exchange and cooperation among medical R&D experts from Korea and Japan."

This content was produced with the assistance of AI translation services.